Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Organovo, Inc.
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
July 16, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
May 21, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
May 14, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
May 08, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
January 25, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
January 09, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 13, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 08, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo to Participate in the H.C. Wainwright Global Investment Conference
September 08, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
August 23, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Announces FXR Program
March 21, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
November 15, 2022
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright